• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 filed by Zymeworks Inc.

    3/5/25 4:41:24 PM ET
    $ZYME
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ZYME alert in real time by email
    S-8 1 d867421ds8.htm S-8 S-8

    As filed with the Securities and Exchange Commission on March 5, 2025

    Registration No. 333-   

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    FORM S-8

    REGISTRATION STATEMENT

    UNDER

    THE SECURITIES ACT OF 1933

     

     

    ZYMEWORKS INC.

    (Exact name of registrant as specified in its charter)

     

     

     

    Delaware   88-3099146

    (State or other jurisdiction of

    incorporation or organization)

     

    (I.R.S. Employer

    Identification No.)

    108 Patriot Drive, Suite A

    Middletown, Delaware 19709

    (Address of principal executive offices, including zip code)

    Amended and Restated Inducement Stock Option and Equity Compensation Plan

    (Full Title of Plan)

    Kenneth Galbraith

    Chair, President and Chief Executive Officer

    108 Patriot Drive, Suite A

    Middletown, Delaware 19709

    (302) 274-8744

    (Name, address and telephone number, including area code, of Agent for Service)

     

     

    Copy to:

    Tony Jeffries

    Bryan D. King

    Wilson Sonsini Goodrich & Rosati, P.C.

    650 Page Mill Road

    Palo Alto, California 94304

    (650) 493-9300

     

     

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

     

    Large accelerated filer   ☐    Accelerated filer   ☐
    Non-accelerated filer   ☒    Smaller reporting company   ☒
         Emerging growth company   ☐

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

     

     

     


    EXPLANATORY NOTE

    Zymeworks Inc. (the “Registrant”) is filing this Registration Statement on Form S-8 with the Securities and Exchange Commission (the “Commission”) to register 700,000 additional shares of the Registrant’s common stock, par value $0.00001 per share, under the Registrant’s Amended and Restated Inducement Stock Option and Equity Compensation Plan (the “Plan”), pursuant to the Registrant’s board of directors’ approval of an amendment and restatement of the Plan and increase to the shares issuable thereunder on July 19, 2024.


    PART I

    INFORMATION REQUIRED IN THE SECTION 10(a) PROSPECTUS

    The information specified in Item 1 and Item 2 of Part I of Form S-8 is omitted from this registration statement in accordance with the provisions of Rule 428 under the Securities Act of 1933, as amended (the “Securities Act”), and the introductory note to Part I of Form S-8. The documents containing the information specified in Part I of Form S-8 will be delivered to the participants in the equity benefit plans covered by this registration statement as specified by Rule 428(b)(1) under the Securities Act.


    PART II

    INFORMATION REQUIRED IN THE REGISTRATION STATEMENT

     

    Item 3.

    Incorporation of Documents by Reference.

    The Registrant hereby incorporates by reference into this registration statement the following documents previously filed with the Commission:

     

    (a)

    the Registrant’s Annual Report on Form 10-K for the fiscal year ended December 31, 2024, filed with the Commission on March 5, 2025;

     

    (b)

    all other reports filed with the Commission pursuant to Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), since the end of the fiscal year covered by the Registrant’s Annual Report on Form 10-K referred to in (a) above; and

     

    (c)

    the description of the Registrant’s common stock contained in the Registrant’s Registration Statement on Form 8-A, as amended by Amendment No. 1 thereto, filed with the Commission on June 12, 2023, including any amendment or report filed for the purpose of updating such description.

    All documents filed by the Registrant pursuant to Sections 13(a), 13(c), 14 and 15(d) of the Exchange Act on or after the date of this registration statement and prior to the filing of a post-effective amendment to this registration statement that indicates that all securities offered have been sold or that deregisters all securities then remaining unsold shall be deemed to be incorporated by reference in this registration statement and to be a part hereof from the date of filing of such documents; provided, however, that documents or information deemed to have been furnished and not filed in accordance with the rules of the Commission shall not be deemed incorporated by reference into this registration statement. Any statement contained in a document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded for purposes of this registration statement to the extent that a statement contained herein or in any subsequently filed document which also is deemed to be incorporated by reference herein modifies or supersedes such statement. Any such statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this registration statement.

     

    Item 4.

    Description of Securities.

    Not applicable.

     

    Item 5.

    Interests of Named Experts and Counsel.

    Not applicable.

     

    Item 6.

    Indemnification of Directors and Officers.

    Section 145 of the Delaware General Corporation Law authorizes a corporation’s board of directors to grant, and authorizes a court to award, indemnity to officers, directors and other corporate agents.

    The Registrant’s certificate of incorporation contains provisions that limit the liability of the Registrant’s directors and certain of the Registrant’s officers for monetary damages to the fullest extent permitted by the Delaware General Corporation Law. Consequently, the Registrant’s directors will not be personally liable to the Registrant’s or the Registrant’s stockholders for monetary damages for any breach of fiduciary duties as directors, except liability for the following:

     

      •  

    any breach of their duty of loyalty to the Registrant or the Registrant’s stockholders;

     

      •  

    any act or omission not in good faith or that involves intentional misconduct or a knowing violation of law;

     

      •  

    unlawful payments of dividends or unlawful stock repurchases or redemptions as provided in Section 174 of the Delaware General Corporation Law; or


      •  

    any transaction from which they derived an improper personal benefit.

    Similarly, the Registrant’s officers who at the time of an act or omission as to which liability is asserted consented to or are deemed to have consented to certain service of process rules under Delaware law will not be personally liable to the Registrant or the Registrant’s stockholders for monetary damages for any breach of fiduciary duties as officers, except for liability in connection with:

     

      •  

    any breach of their duty of loyalty to the Registrant or the Registrant’s stockholders;

     

      •  

    any act or omission not in good faith or that involves intentional misconduct or a knowing violation of law;

     

      •  

    any transaction from which they derived an improper personal benefit; or

     

      •  

    any action by or in the right of the corporation.

    Any amendment, repeal or elimination of these provisions will not eliminate or reduce the effect of these provisions in respect of any act, omission or claim that occurred or arose prior to that amendment, repeal or elimination. If the Delaware General Corporation Law is amended to provide for further limitations on the personal liability of directors or officers of corporations, then the personal liability of the Registrant’s directors and officers will be further limited to the greatest extent permitted by the Delaware General Corporation Law.

    In addition, the Registrant’s bylaws provide that the Registrant will indemnify its directors and officers, and may indemnify its employees, agents and any other persons, to the fullest extent permitted by the Delaware General Corporation Law. The Registrant’s bylaws also provide that the Registrant must advance expenses incurred by or on behalf of a director or officer in advance of the final disposition of any action or proceeding, subject to limited exceptions.

    Further, the Registrant has entered into indemnification agreements with each of its directors and executive officers that may be broader than the specific indemnification provisions contained in the Delaware General Corporation Law. These indemnification agreements require the Registrant to, among other things, indemnify the Registrant’s directors and executive officers against liabilities that may arise by reason of their status or service. These indemnification agreements also generally require the Registrant to advance all expenses reasonably and actually incurred by the Registrant’s directors and executive officers in investigating or defending any such action, suit or proceeding. The Registrant believe that these agreements are necessary to attract and retain qualified individuals to serve as directors and executive officers.

    The limitation of liability and indemnification provisions in the Registrant’s certificate of incorporation, bylaws and indemnification agreements may discourage stockholders from bringing a lawsuit against the Registrant’s directors and officers for breach of their fiduciary duties. They may also reduce the likelihood of derivative litigation against the Registrant’s directors and officers, even though an action, if successful, might benefit the Registrant and other stockholders. Further, a stockholder’s investment may be adversely affected to the extent that the Registrant pays the costs of settlement and damage awards against the Registrant’s directors and officers as required by these indemnification provisions.

    The Registrant has obtained insurance policies under which, subject to the limitations of the policies, coverage is provided to the Registrant’s directors and officers against loss arising from claims made by reason of breach of fiduciary duty or other wrongful acts as a director or officer, including claims relating to public securities matters, and to the Registrant with respect to payments that may be made by the Registrant to its directors and officers pursuant to the Registrant’s indemnification obligations or otherwise as a matter of law.

    Certain of our non-employee directors may, through their relationships with their employers, be insured or indemnified against certain liabilities incurred in their capacity as members of our board of directors.

     

    Item 7.

    Exemption From Registration Claimed.

    Not applicable.


    Item 8.

    Exhibits.

     

    Exhibit

    No.

       Description    Incorporated by Reference     

    Filed

    Herewith

     
       Form     

    File

    Number

        

    Exhibit

    Number

         Filing Date  
      4.1    Specimen common stock certificate of Zymeworks Inc.      S-4/A        333-266160        4.1        August 19, 2022     
      4.2    Amended and Restated Inducement Stock Option and Equity Compensation Plan of the Company (and forms of agreements thereunder)      8-K        001-41535        10.2        July 25, 2024     
      5.1    Opinion of Wilson Sonsini Goodrich & Rosati, P.C.                  X  
     23.1    Consent of Wilson Sonsini Goodrich & Rosati, P.C. (included in Exhibit 5.1 hereto)                  X  
     23.2    Consent of KPMG LLP                  X  
     24.1    Power of Attorney (included on signature page hereto)                  X  
     107    Filing Fee Table                  X  

     

    Item 9.

    Undertakings.

     

    A.

    The undersigned Registrant hereby undertakes:

     

      (1)

    To file, during any period in which offers or sales are being made, a post-effective amendment to this registration statement:

     

      (i)

    to include any prospectus required by Section 10(a)(3) of the Securities Act;

     

      (ii)

    to reflect in the prospectus any facts or events arising after the effective date of the registration statement (or the most recent post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in the registration statement. Notwithstanding the foregoing, any increase or decrease in volume of securities offered (if the total dollar value of securities offered would not exceed that which was registered) and any deviation from the low or high end of the estimated maximum offering range may be reflected in the form of prospectus filed with the Commission pursuant to Rule 424(b) if, in the aggregate, the changes in volume and price represent no more than a 20 percent change in the maximum aggregate offering price set forth in the “Calculation of Filing Fee Table” in the effective registration statement; and

     

      (iii)

    to include any material information with respect to the plan of distribution not previously disclosed in the registration statement or any material change to such information in the registration statement;

    provided, however, that paragraphs (A)(1)(i) and (A)(1)(ii) do not apply if the information required to be included in a post-effective amendment by those paragraphs is contained in reports filed with or furnished to the Commission by the Registrant pursuant to Section 13 or Section 15(d) of the Exchange Act that are incorporated by reference in the registration statement.

     

      (2)

    That, for the purpose of determining any liability under the Securities Act, each such post-effective amendment shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.

     

      (3)

    To remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering.


    B.

    The undersigned Registrant hereby undertakes that, for purposes of determining any liability under the Securities Act, each filing of the Registrant’s annual report pursuant to Section 13(a) or Section 15(d) of the Exchange Act (and, where applicable, each filing of an employee benefit plan’s annual report pursuant to Section 15(d) of the Exchange Act) that is incorporated by reference in the registration statement shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.

     

    C.

    Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers and controlling persons of the Registrant pursuant to the foregoing provisions, or otherwise, the Registrant has been advised that in the opinion of the Commission such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the Registrant of expenses incurred or paid by a director, officer or controlling person of the Registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the Registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Securities Act and will be governed by the final adjudication of such issue.


    SIGNATURES

    Pursuant to the requirements of the Securities Act of 1933, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Middletown, State of Delaware on March 5, 2025.

     

    ZYMEWORKS INC.
    By:   /s/ Kenneth Galbraith
    Name:   Kenneth Galbraith
    Title:   Chair of the Board of Directors,
      President and Chief Executive Officer

    POWER OF ATTORNEY

    KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below hereby constitutes and appoints Kenneth Galbraith and Leone Patterson, and each of them, as his or her true and lawful attorney-in-fact and agent, with full power of substitution and resubstitution, for him or her and in his or her name, place and stead, in any and all capacities, to sign any and all amendments to this registration statement, including post-effective amendments, and to file the same, with all exhibits thereto, and all other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorney-in-fact and agent and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith and about the premises, as fully for all intents and purposes as they, he or she might or could do in person, hereby ratifying and confirming all that said attorney-in-fact and agent or any of them, or their, his or her substitute or substitutes, may lawfully do or cause to be done by virtue hereof.

    Pursuant to the requirements of the Securities Act of 1933, this registration statement has been signed by the following persons in the capacities and on the dates indicated.

     

    Signature    Title   Date

    /s/ Kenneth Galbraith

    Kenneth Galbraith

       Chair of the Board of Directors, President and Chief Executive Officer
    (Principal Executive Officer)
      March 5, 2025

    /s/ Leone Patterson

    Leone Patterson

       Executive Vice President, Chief Business Officer and Chief Financial Officer
    (Principal Financial and Accounting Officer)
      March 5, 2025

    /s/ Carlos Campoy

    Carlos Campoy

       Director   March 5, 2025

    /s/ Alessandra Cesano

    Alessandra Cesano

       Director   March 5, 2025

    /s/ Troy M. Cox

    Troy M. Cox

       Director   March 5, 2025

    /s/ Nancy Davidson

    Nancy Davidson

       Director   March 5, 2025


    /s/ Neil Gallagher

    Neil Gallagher

       Director   March 5, 2025

    /s/ Susan Mahony

    Susan Mahony

       Director   March 5, 2025

    /s/ Derek J. Miller

    Derek J. Miller

       Director   March 5, 2025

    /s/ Kelvin Neu

    Kelvin Neu

       Director   March 5, 2025

    /s/ Oleg Nodelman

    Oleg Nodelman

       Director   March 5, 2025

    /s/ Scott Platshon

    Scott Platshon

       Director   March 5, 2025
    Get the next $ZYME alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ZYME

    DatePrice TargetRatingAnalyst
    12/12/2025$33.00Equal Weight → Overweight
    Wells Fargo
    12/3/2025$32.00Mkt Outperform
    Citizens JMP
    10/24/2025$15.00Equal Weight
    Wells Fargo
    10/14/2025$26.00Neutral → Buy
    H.C. Wainwright
    10/10/2025$30.00Buy
    B. Riley Securities
    5/20/2025Buy
    TD Cowen
    12/16/2024$18.00Neutral → Overweight
    Analyst
    11/7/2024$10.00 → $25.00Market Perform → Outperform
    Leerink Partners
    More analyst ratings

    $ZYME
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Zymeworks Announces Participation in Upcoming Investor Conferences

    VANCOUVER, British Columbia, Jan. 27, 2026 (GLOBE NEWSWIRE) -- Zymeworks Inc. (NASDAQ:ZYME), a biotechnology company managing a portfolio of licensed healthcare assets, while developing a diverse pipeline of novel, multifunctional biotherapeutics, today announced that management will participate in the following upcoming investor conferences: Citi's 2026 Virtual Oncology Leadership Summit: Zymeworks' management will participate in one-on-one meetings February 18-19, 2026 virtually.TD Cowen 46th Annual Health Care Conference: Zymeworks' management will participate in one-on-one meetings and a fireside chat on March 2, 2026 at 14:30 pm – 15:00 pm Eastern Time (ET) in Boston, MA.Leerink Annu

    1/27/26 6:00:00 AM ET
    $ZYME
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Zymeworks Announces Leadership Appointments and Transitions to Align with Evolution of Corporate Strategy

    Investment industry veteran Mr. Brian Cherry appointed to Board of DirectorsDr. Sabeen Mekan to transition to Chief Medical Officer effective February 1, 2026 and Mark Hollywood promoted to Executive Vice President and Chief Operating OfficerFive new Vice Presidents appointed, underscoring our commitment to leadership development VANCOUVER, British Columbia, Jan. 12, 2026 (GLOBE NEWSWIRE) -- Zymeworks Inc. (NASDAQ:ZYME), a biotechnology company managing a portfolio of licensed healthcare assets, while developing a diverse pipeline of novel, multifunctional biotherapeutics, today announced appointments, promotions, retirements, and reductions to its leadership team intended to strengthen t

    1/12/26 6:00:00 AM ET
    $ZYME
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Zymeworks Outlines Strategic Priorities and Outlook for 2026

    Positive Phase 3 HERIZON-GEA-01 results for Ziihera® (zanidatamab-hrii) in first-line HER2-positive (HER2+) gastroesophageal adenocarcinoma (GEA) presented at ASCO GI Up to $440.0 million in milestone payments eligible to be earned related to regulatory approvals of Ziihera in GEA in the United States, Europe, Japan, and ChinaCompany well-positioned to execute new strategy compounding long-term value by integrating royalty growth, strategic acquisitions, and continued internal R&D innovation$125.0 million share repurchase plan announced in November 2025 available to reduce share countCash, cash equivalents, and marketable securities of approximately $270.6 million (unaudited) as of December

    1/11/26 6:00:00 PM ET
    $ZYME
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ZYME
    SEC Filings

    View All

    SEC Form 144 filed by Zymeworks Inc.

    144 - Zymeworks Inc. (0001937653) (Subject)

    1/12/26 5:00:02 PM ET
    $ZYME
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 144 filed by Zymeworks Inc.

    144 - Zymeworks Inc. (0001937653) (Subject)

    1/12/26 5:00:02 PM ET
    $ZYME
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 144 filed by Zymeworks Inc.

    144 - Zymeworks Inc. (0001937653) (Subject)

    1/12/26 5:00:03 PM ET
    $ZYME
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ZYME
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Ecor1 Capital, Llc bought $635,586 worth of shares (55,421 units at $11.47) (SEC Form 4)

    4 - Zymeworks Inc. (0001937653) (Issuer)

    5/19/25 6:35:05 PM ET
    $ZYME
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Ecor1 Capital, Llc bought $1,456,408 worth of shares (128,713 units at $11.32) (SEC Form 4)

    4 - Zymeworks Inc. (0001937653) (Issuer)

    4/18/25 3:17:11 PM ET
    $ZYME
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Ecor1 Capital, Llc bought $3,623,970 worth of shares (317,208 units at $11.42) (SEC Form 4)

    4 - Zymeworks Inc. (0001937653) (Issuer)

    4/7/25 6:34:11 PM ET
    $ZYME
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ZYME
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Zymeworks upgraded by Wells Fargo with a new price target

    Wells Fargo upgraded Zymeworks from Equal Weight to Overweight and set a new price target of $33.00

    12/12/25 8:37:46 AM ET
    $ZYME
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Citizens JMP initiated coverage on Zymeworks with a new price target

    Citizens JMP initiated coverage of Zymeworks with a rating of Mkt Outperform and set a new price target of $32.00

    12/3/25 8:41:52 AM ET
    $ZYME
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Wells Fargo resumed coverage on Zymeworks with a new price target

    Wells Fargo resumed coverage of Zymeworks with a rating of Equal Weight and set a new price target of $15.00

    10/24/25 9:02:46 AM ET
    $ZYME
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ZYME
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    New insider Mekan Sabeen claimed no ownership of stock in the company (SEC Form 3)

    3 - Zymeworks Inc. (0001937653) (Issuer)

    2/2/26 8:37:00 PM ET
    $ZYME
    Biotechnology: Pharmaceutical Preparations
    Health Care

    EVP & Chief Operating Officer Hollywood Mark converted options into 17,666 shares and sold $138,762 worth of shares (6,120 units at $22.67), increasing direct ownership by 10% to 132,913 units (SEC Form 4)

    4 - Zymeworks Inc. (0001937653) (Issuer)

    1/13/26 5:11:03 PM ET
    $ZYME
    Biotechnology: Pharmaceutical Preparations
    Health Care

    New insider Hollywood Mark claimed ownership of 121,367 shares (SEC Form 3)

    3 - Zymeworks Inc. (0001937653) (Issuer)

    1/13/26 5:04:03 PM ET
    $ZYME
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ZYME
    Leadership Updates

    Live Leadership Updates

    View All

    Zymeworks Appoints Scott Platshon as Acting Chief Investment Officer

    VANCOUVER, British Columbia, Nov. 18, 2025 (GLOBE NEWSWIRE) -- Zymeworks Inc. (NASDAQ:ZYME), a biotechnology company managing a portfolio of licensed healthcare assets, while developing a diverse pipeline of novel, multifunctional biotherapeutics today announced the appointment of Scott Platshon as Acting Chief Investment Officer. Mr. Platshon will report directly to Zymeworks' Chair and Chief Executive Officer, Kenneth Galbraith, and work closely with him to manage expected future cash flows from Ziihera® (zanidatamab-hrii) and other healthcare assets and licensed product candidates, such as pasritamig, which is being advanced to Phase 3 registration studies by Johnson & Johnson Innovati

    11/18/25 1:01:00 AM ET
    $ZYME
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Zymeworks Appoints Dr. Adam Schayowitz as Acting Chief Development Officer

    VANCOUVER, British Columbia, Oct. 09, 2025 (GLOBE NEWSWIRE) -- Zymeworks Inc. (NASDAQ:ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, including cancer, inflammation, and autoimmune disease, today announced the appointment of Adam Schayowitz, Ph.D., MBA as Acting Chief Development Officer. In this role, Dr. Schayowitz will report directly to Zymeworks' Chair & Chief Executive Officer, Kenneth Galbraith, and work closely with the Zymeworks R&D and Business Development teams to advance the Company's broad portfolio of nominated product candidates, while also

    10/9/25 6:00:00 AM ET
    $ZYME
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Zymeworks Strengthens Board of Directors with Appointments of Greg Ciongoli and Robert E. Landry

    VANCOUVER, British Columbia, Aug. 11, 2025 (GLOBE NEWSWIRE) -- Zymeworks Inc. (NASDAQ:ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, including cancer, inflammation, and autoimmune disease, today announced the appointments of Greg Ciongoli and Robert E. Landry to the Company's Board of Directors, effective August 10, 2025. Mr. Ciongoli and Mr. Landry were also appointed as members of the audit committee of the Board of Directors. "Greg and Bob bring extensive financial and strategic leadership expertise that will be invaluable to Zymeworks, as we continu

    8/11/25 6:00:00 AM ET
    $ZYME
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ZYME
    Financials

    Live finance-specific insights

    View All

    Zymeworks Announces Strategic Initiative to Optimize Value of Licensed Products by Building a Diversified Portfolio of Revenue-Generating Assets

    Strategy will combine internal innovation, licensing, and strategic acquisitions to drive sustainable value creation for shareholdersStrategic initiative follows positive topline results from pivotal Phase 3 HERIZON-GEA-01 trial evaluating zanidatamab in first-line gastroesophageal adenocarcinoma (GEA) and pasritamig advancing to registration studies by J&J Innovative Medicine (J&J)Eligible to receive up to $440.0 million in potential near-term milestone payments upon successful global regulatory approvals of Ziihera® in GEA Successful commercialization of Ziihera and execution of partnership strategy are expected to drive substantial royalty and milestone revenues with carefully managed R&D

    11/18/25 1:00:00 AM ET
    $ZYME
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Zymeworks to Report Third Quarter 2025 Financial Results and Host Conference Call on November 6, 2025

    VANCOUVER, British Columbia, Oct. 16, 2025 (GLOBE NEWSWIRE) -- Zymeworks Inc. (NASDAQ:ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, including cancer, inflammation, and autoimmune disease, today announced that management will report its third quarter 2025 financial results after market close on November 6, 2025. Following the announcement, management will host a conference call and webcast to discuss financial results and provide a corporate update on November 6, 2025 at 4:30 pm Eastern Time (ET). The event will be webcast live with dial-in details and w

    10/16/25 6:00:00 AM ET
    $ZYME
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Zymeworks Provides Corporate Update and Reports Second Quarter 2025 Financial Results

    Investigational new drug (IND) application cleared by the United States Food and Drug Administration (FDA) for ZW251 with first-in-human studies planned to initiate in 2025China and European approval for zanidatamab in 2L HER2-positive biliary tract cancer (BTC) expands international patient access$48.7 million in revenue for 2Q-2025 from continued progress on existing partnerships Ziihera® net product sales by Jazz were $5.5 million for 2Q-2025Cash resources of $333.4 million as of June 30, 2025 (compared to $324.2 million as of December 31, 2024), which when combined with certain anticipated regulatory milestone payments, provides a projected cash runway into 2H-2027Will host conference ca

    8/7/25 4:05:00 PM ET
    $ZYME
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ZYME
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Zymeworks Inc.

    SC 13G/A - Zymeworks Inc. (0001937653) (Subject)

    11/14/24 9:00:57 PM ET
    $ZYME
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Zymeworks Inc.

    SC 13G/A - Zymeworks Inc. (0001937653) (Subject)

    11/14/24 4:27:20 PM ET
    $ZYME
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Zymeworks Inc.

    SC 13G - Zymeworks Inc. (0001937653) (Subject)

    11/13/24 4:30:24 PM ET
    $ZYME
    Biotechnology: Pharmaceutical Preparations
    Health Care